Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Genet., 28 September 2022

Sec. Cancer Genetics and Oncogenomics

Volume 13 - 2022 | https://doi.org/10.3389/fgene.2022.878123

RETRACTED: Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients

Retracted

A retraction of this article was approved in:

  1. Retraction: Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients

    1. Read retraction
Mi Jiao,&#x;Mi Jiao1,2†Wenbo Sun&#x;Wenbo Sun2†Lina LiLina Li2Chunyan LiChunyan Li2Jing ZhouJing Zhou2Qian LiQian Li2Lian Duan Lian Duan1*
  • 1Xi’an Jiaotong University Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
  • 2Department of Medical Oncology, Shaanxi Provincial Cancer Hospital Affiliated to Xi’an Jiaotong University Medical College, Xi’an, Shaanxi, China

This article has been retracted. Please follow the link to the full Retraction notice for details.

Citation: Jiao M, Sun W, Li L, Li C, Zhou J, Li Q and Duan L (2022) Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients. Front. Genet. 13:878123. doi: 10.3389/fgene.2022.878123

Received: 17 February 2022; Accepted: 05 September 2022;
Published: 28 September 2022; Retracted: 14 January 2026.

Edited by:

Yongwen Luo, Zhongnan Hospital, Wuhan University, China

Reviewed by:

Rourou Xiao, Zhongnan Hospital, Wuhan University, China
Dan Sun, The First Affiliated Hospital of China Medical University, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.